# CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

> **NCT01835041** · PHASE1 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 21 (actual)

## Conditions studied

- Acinar Cell Adenocarcinoma of the Pancreas
- Duct Cell Adenocarcinoma of the Pancreas
- Recurrent Pancreatic Cancer
- Stage IV Pancreatic Cancer

## Interventions

- **DRUG:** 6,8-bis(benzylthio)octanoic acid
- **DRUG:** oxaliplatin
- **DRUG:** leucovorin calcium
- **DRUG:** irinotecan hydrochloride
- **DRUG:** fluorouracil
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01835041
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2017-02-28
- **Final completion:** 2023-03-16
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2023-07-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01835041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01835041, "CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01835041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*